Prime Medicine, Inc.
PRME
$3.09
-$0.08-2.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.50% | -41.13% | -61.61% | 486.12% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.50% | -41.13% | -61.61% | 486.12% | -- |
| Cost of Revenue | -19.28% | -15.92% | 1.77% | 9.05% | -3.94% |
| Gross Profit | 19.91% | 14.98% | -6.11% | -6.56% | 6.53% |
| SG&A Expenses | -15.82% | 31.02% | 19.80% | -20.52% | 4.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.45% | -4.34% | 6.55% | 1.39% | -2.12% |
| Operating Income | 18.91% | 3.32% | -9.92% | 0.48% | 4.12% |
| Income Before Tax | 19.93% | 5.33% | -9.00% | 3.69% | 5.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.93% | 5.33% | -9.00% | 3.69% | 4.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.93% | 5.33% | -9.00% | 3.69% | 4.95% |
| EBIT | 18.91% | 3.32% | -9.92% | 0.48% | 4.12% |
| EBITDA | 19.44% | 3.74% | -9.94% | 1.10% | 4.84% |
| EPS Basic | 41.64% | 30.04% | 19.51% | 28.14% | 12.30% |
| Normalized Basic EPS | 41.20% | 28.40% | 17.78% | 26.52% | 11.75% |
| EPS Diluted | 41.64% | 30.04% | 19.51% | 28.14% | 12.30% |
| Normalized Diluted EPS | 41.20% | 28.40% | 17.78% | 26.52% | 11.75% |
| Average Basic Shares Outstanding | 37.19% | 35.31% | 35.42% | 34.02% | 8.39% |
| Average Diluted Shares Outstanding | 37.19% | 35.31% | 35.42% | 34.02% | 8.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |